SABCS 2011: CLEOPATRA trial, efficacy and safety of pertuzumab, trastuzumab, docetaxel

For more videos from SABCS 2011 and on breast cancer visit ecancer.org/tv

At a press conference at the annual ASH meeting 2011, Porf Jose Baselga discusses te CLEOPATRA trial.

Background information from the abstract states: pertuzumab (P) is a fully humanised investigational monoclonal antibody that binds to human epidermal growth factor receptor 2 (HER2), preventing dimerization of HER2 with other HER family members and inducing antibody-dependent cell-mediated cytotoxicity.

Its mechanisms of action are complementary to those of the anti-HER2 antibody trastuzumab (H) and the two antibodies combined have superior activity compared with either antibody alone in preclinical and clinical studies. In patients with advanced disease, P in combination with H has been shown to be active in patients whose disease has progressed while on H therapy (Baselga et al. J Clin Oncol 2010).

Category:

Science & Technology

Tags:

• CLEOPATRA
• baselga
• mass general hospital
• mit
• cancer
• oncology
• breast cancer
• sabcs 2011